Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Ceflatonin
2. Cephalotaxine
3. Homoharringtonine
4. Homoharringtonine (3(r))-isomer
5. Omacetaxine
6. Synribo
1. Homoharringtonine
2. Ceflatonin
3. Myelostat
4. 26833-87-4
5. Synribo
6. Cgx-635
7. Omapro
8. Homoharringtonin
9. (-)-homoharringtonine
10. Nsc-141633
11. C29h39no9
12. Chebi:71019
13. (2'r,3s,4s,5r)-(-)-homoharringtonine
14. Omacetaxine (homoharringtonine)
15. Omacetaxine Mepesuccinate [usan]
16. 6fg8041s5b
17. Nsc 141633
18. 1-o-[(2s,3s,6r)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-o-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
19. Cephalotaxine 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
20. Omacetaxine Mepesuccinate (usan)
21. Tekinex
22. Synribo (tn)
23. Cephalotaxine, 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
24. Unii-6fg8041s5b
25. Nsc141633
26. Ncgc00025155-01
27. Omacetaxine Mepesuccinate [usan:inn]
28. Brn 5687925
29. Omacetaxini Mepesuccinas
30. Zj-c
31. Mepesuccinate D'omacetaxine
32. Mepesuccinato De Omacetaxina
33. Cephalotaxine 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
34. Mls001424293
35. Chembl46286
36. Homoharringtonine [mi]
37. Cgx-635-14 (formulation)
38. Gtpl7454
39. Schembl12745687
40. Hms3267h22
41. Hms3414n05
42. Hms3678n03
43. Amy33459
44. Homoharringtonine, >=98% (hplc)
45. Bdbm50480293
46. Mfcd05618221
47. Nsc758253
48. S9015
49. Zinc26011099
50. Akos024456585
51. Ccg-269981
52. Db04865
53. Nc00395
54. Nsc-758253
55. Omacetaxine Mepesuccinate [inn]
56. Ncgc00025155-02
57. Ncgc00025155-03
58. Ncgc00025155-04
59. Ncgc00025155-07
60. Omacetaxine Mepesuccinate [mart.]
61. Omacetaxine Mepesuccinate [vandf]
62. Hy-14944
63. Nci60_000917
64. Omacetaxine Mepesuccinate [who-dd]
65. Smr000469230
66. H1775
67. N1504
68. D08956
69. Omacetaxine Mepesuccinate [orange Book]
70. Ab00642561-02
71. Sr-01000597562
72. Q7089373
73. Sr-01000597562-1
74. Brd-k76674262-001-01-7
75. Brd-k76674262-001-02-5
76. Cephalotaxine, 3-[4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate]
77. Cephalotaxine, 4-methyl-, 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
78. (s)-1-((11bs,12s,14ar)-13-methoxy-2,3,5,6,11b,12-hexahydro-1h-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-yl) 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)succinate
79. 1-((1s,3ar,14bs)-2-methoxy-1,5,6,8,9,14b-hexahydro-4h- Cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2r)-2- Hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
80. 1-((1s,3ar,14bs)-2-methoxy-1,5,6,8,9,14b-hexahydro-4h-cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
81. Homoharringtonine; Cephalotaxine; [3(r)]-4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
Molecular Weight | 545.6 g/mol |
---|---|
Molecular Formula | C29H39NO9 |
XLogP3 | 0.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 11 |
Exact Mass | 545.26248182 g/mol |
Monoisotopic Mass | 545.26248182 g/mol |
Topological Polar Surface Area | 124 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 968 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Synribo |
PubMed Health | Omacetaxine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | SYNRIBO contains the active ingredient omacetaxine mepesuccinate, a cephalotaxine ester. It is a protein synthesis inhibitor. Omacetaxine mepesuccinate is prepared by a semi-synthetic process from cephalotaxine, an extract from the leaves of Cephalot... |
Active Ingredient | Omacetaxine mepesuccinate |
Dosage Form | Powder |
Route | Subcutaneous |
Strength | 3.5mg/vial |
Market Status | Prescription |
Company | Ivax Intl |
2 of 2 | |
---|---|
Drug Name | Synribo |
PubMed Health | Omacetaxine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | SYNRIBO contains the active ingredient omacetaxine mepesuccinate, a cephalotaxine ester. It is a protein synthesis inhibitor. Omacetaxine mepesuccinate is prepared by a semi-synthetic process from cephalotaxine, an extract from the leaves of Cephalot... |
Active Ingredient | Omacetaxine mepesuccinate |
Dosage Form | Powder |
Route | Subcutaneous |
Strength | 3.5mg/vial |
Market Status | Prescription |
Company | Ivax Intl |
Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
FDA Label
Philadelphia chromosome positive chronic myeloid leukaemia in patients who have the T315I Bcr-Abl kinase domain mutation and who are resistant to prior imatinib therapy.
The pharmacodynamics of homoharringtonine is not fully understood. It is known that homoharringtonine is involved with protein synthesis inhibition and this leads to its antineoplastic activity.
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XX - Other antineoplastic agents
L01XX40 - Omacetaxine mepesuccinate
Absorption
Homoharringtonine absorption was not quantified, but maximum concentration is reached after about 30 mins.
Route of Elimination
The main route of elimination for homoharringtonine is still unknown, but renal elimination is less than 15%.
Volume of Distribution
Homoharringtonine has a steady state Vd of 141 93.4 L.
Clearance
Clearance for homoharringtonine was not quantified.
Homoharringtonine has undergoes little hepatic metabolism and is mostly metabolized to 4-DMHHT by plasma esterase hydrolysis.
Homoharringtonine has a half life of about 6 hours after subcutaneous administration.
Homoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Homoharringtonine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Homoharringtonine, including repackagers and relabelers. The FDA regulates Homoharringtonine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Homoharringtonine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Homoharringtonine supplier is an individual or a company that provides Homoharringtonine active pharmaceutical ingredient (API) or Homoharringtonine finished formulations upon request. The Homoharringtonine suppliers may include Homoharringtonine API manufacturers, exporters, distributors and traders.
click here to find a list of Homoharringtonine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Homoharringtonine DMF (Drug Master File) is a document detailing the whole manufacturing process of Homoharringtonine active pharmaceutical ingredient (API) in detail. Different forms of Homoharringtonine DMFs exist exist since differing nations have different regulations, such as Homoharringtonine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Homoharringtonine DMF submitted to regulatory agencies in the US is known as a USDMF. Homoharringtonine USDMF includes data on Homoharringtonine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Homoharringtonine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Homoharringtonine suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Homoharringtonine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Homoharringtonine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Homoharringtonine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Homoharringtonine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Homoharringtonine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Homoharringtonine suppliers with NDC on PharmaCompass.
Homoharringtonine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Homoharringtonine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Homoharringtonine GMP manufacturer or Homoharringtonine GMP API supplier for your needs.
A Homoharringtonine CoA (Certificate of Analysis) is a formal document that attests to Homoharringtonine's compliance with Homoharringtonine specifications and serves as a tool for batch-level quality control.
Homoharringtonine CoA mostly includes findings from lab analyses of a specific batch. For each Homoharringtonine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Homoharringtonine may be tested according to a variety of international standards, such as European Pharmacopoeia (Homoharringtonine EP), Homoharringtonine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Homoharringtonine USP).
LOOKING FOR A SUPPLIER?